(Press-News.org) New York, NY (November 10 2025) — In a high honor, Jean-Frédéric Colombel, MD, a leading inflammatory bowel disease (IBD) expert at the Icahn School of Medicine at Mount Sinai, will deliver the 31st Anatomy Lesson on Thursday, November 20, at the Concertgebouw in Amsterdam. His lecture, “Tackling the Growing Problem of Immune Diseases—Crohn’s Disease as an Example,” will explore Mount Sinai’s pioneering work in the early detection, prevention, and treatment of IBD.
The Anatomy Lesson, an annual public lecture organized by Amsterdam UMC, invites leading international physicians and researchers to reflect on medicine’s evolving relationship with society. Dr. Colombel’s presentation will highlight how Mount Sinai and international collaborators are moving closer to the long-sought goal of preventing immune diseases before they begin.
Crohn’s disease and ulcerative colitis—debilitating inflammatory bowel disorders that often strike people in their 20s and 30s—can upend young lives just as careers, families, and relationships begin to form. Dr. Colombel has dedicated nearly five decades to restoring quality of life for these patients while pursuing the goal of discovering the cause of Crohn’s disease and, ultimately, a cure.
Dr. Colombel is Professor of Medicine (Gastroenterology) and Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai. He is internationally recognized for his discoveries that have reshaped how clinicians understand and diagnose IBD. His research has revealed early disease biomarkers such as the ASCA blood test, identified genetic drivers including the NOD2 mutation, and characterized disease-associated gut bacteria. These findings allow physicians to identify patients at increased risk of IBD—even before symptoms develop—and to intervene earlier with personalized care strategies.
“The earlier we can detect inflammation and intervene, the greater our chances of altering the course of disease and preserving a patient’s life plans,” said Dr. Colombel. “At Mount Sinai, we are driven by one mission: to give our patients their lives back—not just through medication or surgery, but by finding and addressing the root causes of IBD.”
Dr. Colombel’s current collaborations include INTERCEPT, a large European study on the early prediction and prevention of Crohn’s disease, and work with the U.S. Department of Defense Serum Repository, which houses more than 80 million blood samples. These studies aim to identify biological “signatures” years before clinical onset—potentially transforming how autoimmune and inflammatory diseases such as IBD, diabetes, rheumatoid arthritis, and multiple sclerosis are managed.
“Jean-Frédéric Colombel has advanced the field of gastroenterology through relentless curiosity and compassion for his patients,” said Bruce E. Sands, MD, MS, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai. “His leadership in early detection, precision medicine, and translational research continues to shape our understanding of Crohn’s disease and drives innovation across our entire digestive health enterprise.”
Mount Sinai’s Feinstein IBD Center, one of the largest and most comprehensive programs of its kind, has become a global hub for IBD research, patient care, and clinical innovation. The Center’s multidisciplinary
teams integrate advanced genomics, microbiome analysis, and digital health data to develop personalized treatment approaches that improve remission rates and long-term outcomes.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2025-2026.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
END
Mount Sinai’s Jean-Frédéric Colombel, MD, to deliver the 31st Anatomy Lesson in Amsterdam, highlighting global efforts to prevent and cure Crohn’s disease
2025-11-10
ELSE PRESS RELEASES FROM THIS DATE:
Breast cancer case study could inform clinical trials
2025-11-10
When researchers look for potential cancer therapy targets, they typically go after protein-coding genes that participate in disease progression. Disrupt them and negate whatever role they play in cancer’s development or spread. Researchers at Cold Spring Harbor Laboratory (CSHL) have also been working on another kind of target. They’re studying a long non-coding RNA called MALAT1. So far, it’s been linked to more than 20 different types of tumors.
In a new and unique study published in Molecular Therapy: Oncology, CSHL researchers track MALAT1 levels ...
Cherie Zachary, MD, installed as ACAAI President
2025-11-10
ORLANDO (NOV. 9, 2025) – Allergist Cherie Zachary, MD, of Bloomington, MN was installed as president of the American College of Allergy, Asthma and Immunology (ACAAI) at the ACAAI Annual Scientific Meeting on November 10 in Orlando. Allergist David Stukus, MD, of Columbus, OH, was elected ACAAI president-elect.
Other newly-elected ACAAI officers are Maureen Petersen, MD, of Clayton, NC, as vice president and Melinda Rathkopf, MD, MBA, of Atlanta, GA, as treasurer. Regents elected for three-year terms include Christopher C. Chang, MD, PhD, MBA, Hollywood, Florida, Mitchell H. Grayson, MD, Columbus, OH, and Jay A. Lieberman, ...
Billions live in environments that violate human rights
2025-11-10
More than 99% of the world’s 7.7 billion people have one or more of their environmental rights threatened, according to new research.
In the most comprehensive analysis of inequality in environmental conditions to date, CU Boulder researchers revealed that nearly half of the global population lives in regions facing three or more environmental problems. Those include polluted air, unsafe water, extreme heat, food insecurity and biodiversity loss.
The analysis was published September 25 in Environmental Research Communications.
It provides strong ...
Thyroid gland new possible target for prostate cancer treatment
2025-11-10
A hormone produced in the thyroid gland can play a key role in the development of prostate cancer. This is shown in a new study by an international research group led by Umeå University, Sweden, and the Medical University of Vienna, Austria. By blocking a receptor for the hormone, the growth of tumour cells in the prostate was inhibited. In the long term, the discovery may open up a new way of attacking certain types of aggressive prostate cancer.
"The results indicate that the receptor in question is a driving force in the growth of cancer. Substances that block it could thus be a target for future drugs against prostate cancer," ...
New study reveals devastating impact of cane toads approaching the Pilbara
2025-11-10
New Curtin University research has found invasive cane toads are on track to reach Western Australia’s Pilbara region within the next 10 to 20 years, threatening to cause widespread losses among native species and significant cultural and economic harm.
The study, published in Scientific Reports, predicts that without containment efforts, the toxic amphibians will colonise up to 75 per cent of the Pilbara within three decades, putting 25 native species at risk of serious population declines. These include several species of native marsupial predators like northern quolls, ghost bat and kaluta, as well as frog-eating snakes, blue-tongue skinks and goannas.
Of ...
COP30: Global nature goals at risk as conservation projects quietly fail
2025-11-10
As world leaders begin COP30 climate negotiations in Brazil this week, an international team co-led by a University of Sydney researcher has warned of a hidden crisis undermining global biodiversity and carbon targets: the quiet abandonment of conservation projects.
The comment paper, ‘Conservation abandonment is a policy blind spot’, published in Nature Ecology & Evolution, was co-led by Dr Matthew Clark, a postdoctoral researcher in the Thriving Oceans Research Hub at the University of Sydney and an honorary research associate in the Centre for Environmental Policy at Imperial College ...
New treatment for combating iron deficiency more effectively
2025-11-10
Iron deficiency is globally widespread. Women are particularly affected, with one in five in Europe suffering from iron deficiency. The consequences are anaemia, constant fatigue, chronic headaches and a weakened immune system. Researchers led by ETH professor Raffaele Mezzenga have now developed a new dietary supplement that could efficiently treat iron deficiency and anaemia. This development is being co-led by Michael B. Zimmermann, professor emeritus at ETH Zurich. The preparation consists of edible oat protein ...
A new AI-powered method to automate material analysis and design
2025-11-10
Understanding the properties of different materials is an important step in material design. X-ray absorption spectroscopy (XAS) is an important technique for this, as it reveals detailed insights about a material’s composition, structure, and functional characteristics. The technique works by directing a beam of high-energy X-rays at a sample and recording how X-rays of different energy levels are absorbed. Similar to how white light splits into a rainbow after passing through a prism, XAS produces a spectrum of X-rays with different energies. This spectrum is called as spectral data, which acts like an unique fingerprint of a material, ...
Security flaws in portable genetic sequencers risk leaking private DNA data
2025-11-10
Portable genetic sequencers used around the world to sequence DNA have critical, previously unreported security vulnerabilities that could reveal or alter genetic information without detection, according to a new study.
Researchers from the University of Florida have, for the first time, exposed these security risks in devices from Oxford Nanopore Technologies, which produces nearly all the portable genetic sequencers in the world.
Alerted by the security researchers, Oxford Nanopore Technologies has rolled out updated software to patch the vulnerabilities. But out-of-date software, or unsecured internet systems, could still leave some DNA sequencers vulnerable ...
‘Roadmap’ shows the environmental impact of AI data center boom
2025-11-10
ITHACA, N.Y. - As the everyday use of AI has exploded in recent years, so have the energy demands of the computing infrastructure that supports it. But the environmental toll of these large data centers, which suck up gigawatts of power and require vast amounts of water for cooling, has been too diffuse and difficult to quantify.
Now, Cornell researchers have used advanced data analytics – and, naturally, some AI, too – to create a state-by-state look at that environmental impact. The team found that, by 2030, the current rate of AI growth would annually put 24 to 44 million metric tons of carbon dioxide into the ...